The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. DMK Pharmaceuticals's Revenue for the
three
months ended in Sep. 2023 was $0.01 Mil. DMK Pharmaceuticals's average Accounts Receivable for the
three
months ended in Sep. 2023 was $0.00 Mil.
DMK Pharmaceuticals Receivables Turnover Historical Data
The historical data trend for DMK Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DMK Pharmaceuticals's Receivables Turnover
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals's Receivables Turnover Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
DMK Pharmaceuticals Receivables Turnover Related Terms
Thank you for viewing the detailed overview of DMK Pharmaceuticals's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMKPQ has been successfully added to your 